[The therapeutic effects of tumor necrosis factor-alpha monoclonal antibody on hepatopulmonary syndrome in rats].
OBJECTIVE
To investigate the therapeutic effects of tumor necrosis factor-alpha monoclonal antibody on hepatopulmonary syndrome in rats.


METHODS
60 adult male Sprague-Dawley rats, weighing 250+/-25 g, were randomly divided into 3 groups: sham operation (6 rats) group, CBDL (30 rats) group and CBDL+TNF-alpha mAb (24 rats) group. Then CBDL operation group was divided into 5 subgroups and the CBDL+TNF-alpha mAb group was divided into 4 subgroups. Then the rats were sacrificed and the liver tissues were removed, then HE and Masson staining was performed to observe the extent of fibrosis. The arterial blood were gotten for analysis of blood gas and observing the change of alveoloarterial oxygen difference. The change of liver function, the concentration of endotoxin, TNF-alpha and NO were detected.


RESULTS
Compared with the CBDL group, the alveoloarterial oxygen difference decreased significantly in CBDL+TNF-alpha mAb group. And the serum levels of ALT, TBIL decreased obviously. The concentration of ETX, TNF-alpha and NO in CBDL+TNF-alpha mAb group were significantly lower than those in CBDL group.


CONCLUSIONS
There are some therapeutic effects of tumor necrosis factor-alpha antibody on hepatopulmonary syndrome in rats.
Zhao
Zhi
Z
Department of Gastroenterology, the Second Hospital, Hebei Medical University, Shijiazhuang 050000, China. danzhi207@163.com
Liu
Li
L
Liu
Nan
N
Wu
Ya-li
YL
Fu
Jie
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D020065:Hepatopulmonary Syndrome / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D009569:Nitric Oxide / Q000276:immunology; D011897:Random Allocation; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide